Salute e Benessere

Buyback of Class B shares in Essity during week 45, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
11/11/2024

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing…

– RTX001 has recently entered into a Phase 1/2 interventional study in end-stage liver disease. – RTX001 has recently entered into a Phase 1/2 interventional study in end-stage liver disease. EDINBURGH, ScotlandandLONDON , Nov. 11, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company spun out of theUniversity of Edinburghpioneering regenerative macrophage therapy in inflammatory and fibrotic diseases,...
PR Newswire
11/11/2024

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3…

The Phase 1 clinical study enrolled 42 patients across five dose escalation cohorts ranging from 60mg to 200mg and explored daily and thrice weekly oral dosing regimens. Data presented at SITC follows the Company's presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024. The Phase 1 clinical study enrolled 42 patients across five dose escalation cohorts ranging from 60mg to 200mg and explored daily and thrice weekly oral dosing regimens...
PR Newswire
11/11/2024

Huion's Early Black Friday Deals Go Live on Nov 11

Kamvas Pro 19 Kamvas Pro 19 Take the US site of Huion's official store as an example (to check specific discounts for your location, please visit the corresponding site in your area). During the sale, the price of Kamvas Pro 19 will drop to$879, saving you$220off its MSRP of$1,099. This is a record-low price since its release. Featuring the latest Huion PenTech 4.0 technology, Kamvas Pro 19 boasts16Klevels of pressure sensitivity, ensuring more delicate and smooth line...
PR Newswire
11/11/2024

EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver…

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy for individuals with liver disease Glasgow, Scotland – 11 November 2024.EnteroBiotix Limited ('EnteroBiotix' or the 'Company'), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced positive results from its...
Nasdaq GlobeNewswire
11/11/2024

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

Right to participate and registration Right to participate and registration (A) Participation at the meeting venue A person who wishes to attend the meeting venue in person or by proxy must If the shareholder is represented by proxy, a written and dated power of attorney signed by the shareholder shall be issued for the proxy. Proxy forms are available at the company's websitewww.sobi.com. If the power of attorney has been issued by a legal entity, a registration certificate or...
PR Newswire
11/11/2024

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product…

OMPD will offer Neurizon a range of attractive incentives for NUZ-001. These include reduced regulatory fees, free protocol assistance, and, importantly, 10 years of market exclusivity in the European Union (EU). During the exclusivity period, the EMA and the EU Member States will not accept another marketing authorisation application for a similar medicinal product in the same therapeutic indication. OMPD will offer Neurizon a range of attractive incentives for NUZ-001. These include reduced...
PR Newswire
11/11/2024

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second…

Nine-month Results Remain On Track for Net ProfitAd Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 11, 2024-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024. The provisional result for the third...
Nasdaq GlobeNewswire
11/11/2024

China's Pioneer Hemodialysis Company to Attend MEDICA 2024

At MEDICA, the company will showcase three flagship hemodialysis machines: At MEDICA, the company will showcase three flagship hemodialysis machines: "Over the years, our dedicated SWS team has transformed the company from a start-up into a leader in the blood purification equipment industry. SWS epitomizes the rise of Chinese medical device enterprises globally. We are committed to fostering a brand that empowers kidney patients worldwide" GAO Guangyong, Chairman of SWS Medical. Based…
PR Newswire
11/11/2024

TB Alliance Joins Indonesia's High-Level Meeting on TB

The meeting will feature a series of expert panels that will delve into comprehensive analyses of the current state of TB, alongside forward-looking strategies that prioritize groundbreaking solutions in treatment, diagnostics, and vaccine development. Representing TB Alliance, Dr. Mel Spigelman, President and CEO, Dr. Eugene Sun, Senior Vice President of R&D, and Sandeep Juneja, Senior Vice President of Market Access, will speak on panels addressing the transformation of TB research and…
PR Newswire
11/11/2024

KFSHRC's New US Patent Opens New Frontiers for Breast Cancer Treatment

RIYADH, Saudi Arabia, Nov.10, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) announced a significant advancement in stem cell science, securing a U.S. patent for an innovative method that holds promise for breast cancer treatment and regenerative medicine.This innovative approach, developed by KFSHRC researchers Abdelilah Aboussekhra, Huda H. Al-Khalaf, and Hazem Ghebeh, involves transforming regular breast cells into multipotent stem cells...
Nasdaq GlobeNewswire
10/11/2024

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the…

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancersACTengine® IMA203 demonstrates 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses; Company plans to start its randomized-controlled Phase 3 SUPRAME trial in December 2024 to evaluate...
Nasdaq GlobeNewswire
08/11/2024

Teva to Present at the Jefferies London Healthcare Conference

To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded...
Nasdaq GlobeNewswire
08/11/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 8 November 2024– This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
08/11/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 8 November 2024– The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 3,136,206,122.30 in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).The purpose of the...
Nasdaq GlobeNewswire
08/11/2024

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings…

Bagsværd, Denmark, 8 November 2024– Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 750.42 per share and has been calculated as the three-day volume weighted average market price...
Nasdaq GlobeNewswire
08/11/2024

Global Infusion Pumps Market Projected to Reach $14.7 Billion by 2029

This report provides an in-depth analysis of the infusion pump market, including the market shares of leading companies. The market is segmented by product types, including general-purpose infusion pumps, such as large-volume, syringe, electronic ambulatory, and elastomeric pumps, as well as specialty pumps such as insulin, patient-controlled analgesia, enteral, and implantable infusion pumps. The report focuses on application areas such as diabetes management, pain management/analgesia…
PR Newswire
08/11/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of October 31, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (November 8, 2024 - 6:00 pm)– As of October 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down...
Nasdaq GlobeNewswire
08/11/2024

Monthly information related to total number of voting rights and shares…

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)voting rightsTotal of net(2)voting rights December 31, 20236...
Nasdaq GlobeNewswire
08/11/2024

Medical Device Packaging Market Poised for Significant Expansion, Projected to…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1062219 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1062219 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Medical Device Packaging Market Overview Market Size and Growth The Medical Device Packaging Market is experiencing significant growth, projected to expand from approximatelyUSD 37.4 billionin 2024 toUSD 56.1 billion...
PR Newswire
08/11/2024

Physiotherapy Equipment Market to Hit USD 27.03 Billion by 2029 with 6.1% CAGR |…

Browse in-depth TOC on "Physiotherapy Equipment Market" Browse in-depth TOC on "Physiotherapy Equipment Market" 173 - Tables40 - Figures250 - Pages By product,the physiotherapy equipment market is segmented into equipment and accessories. In 2023, the equipment segment accounted for largest share in the physiotherapy equipment market due to essential role of physiotherapy equipment's in rehabilitative care. The demand for physiotherapy equipment such as electrotherapy,...
PR Newswire
08/11/2024

TESTCARD TEST KIT: GROUNDBREAKING NEW TRIAL FOR PROSTATE CANCER SCREENING IN THE…

Historically, prostate cancer screening has required patients to travel to a clinic for a blood test and then travel again to receive their results. These friction points during screening can cause patients to put off their appointments or not to attend at all. Historically, prostate cancer screening has required patients to travel to a clinic for a blood test and then travel again to receive their results. These friction points during screening can cause patients to put off their…
PR Newswire
08/11/2024

Anesthesia Monitoring Devices Market is expected to generate a revenue of USD…

The healthcare industry faces increasing pressure to deliver precision care, with anesthesia monitoring devices at the core of safe and effective patient management. Our research identifies the market's key growth drivers, from technological advancements in sensor technology to the rising adoption of minimally invasive surgeries. This report will equip decision-makers with the knowledge needed to capitalize on emerging trends and address the challenges of regulatory compliance and technological…
PR Newswire
08/11/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 8 November 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
08/11/2024
Altri  Comunicati